3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
24
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Biochemically Recurrent Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
durvalumab
3
abemaciclib
3
Fulvestrant
3
Cisplatin
3
ribociclib
2
pembrolizumab
2
palbociclib
2
Pemetrexed
2
Nivolumab
2
Letrozole
2
Carboplatin
2
Bevacizumab
2
Anastrozole
2
130-nm albumin-bound paclitaxel
2
selpercatinib
1
selinexor
1
repotrectinib
1
relatlimab
1
relacorilant
1
olaparib
1
gallium 68 PSMA-11
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
darolutamide
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
Sunitinib
1
STX-478
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
darolutamide
×
90 days
×
Clear all
NCT07103018
2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1
Recruiting
144 enrolled